Abstract
Chronic myocarditis is a prolonged inflammatory condition in the myocardium and its histological manifestation is defined by the presence of an inflammatory infiltrate. Chronic myocarditis has not been well known and its treatment of chronic myocarditis has not been established. Primary outcome of this study was to assess the efficacy of immunomodulatory treatment in addition to conventional treatment, and secondary outcomes were to clarity the prognosis of natural history of chronic myocarditis and incidence of chronic myocarditis in patients with dilated cardiomyopathy (DCM). We searched for studies in Medline, Embase, Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi published between January 1946 and June 2020. Sixteen studies met the inclusion criteria. A meta-analysis revealed that patients receiving immunomodulatory treatment showed an improvement in left ventricular ejection fraction after immunomodulatory treatment compared to the control group (hazard ratio, 16.65; confidence interval, 4.55–28.74; p = 0.007). Five-year survival rate of the patients with inflammatory DCM (iDCM) and DCM was 52.7–70.3% and 51.9–91.1%, respectively. Moreover, 51.5%–62.7% of patients with DCM met the criteria of iDCM. Our systematic review revealed that patients with chronic myocarditis had poor prognosis and immunomodulatory treatment was significantly effective in addition to conventional treatment.
Similar content being viewed by others
Abbreviations
- DCM:
-
Dilated cardiomyopathy
- iDCM:
-
Inflammatory dilated cardiomyopathy
- EMB:
-
Endomyocardial biopsy
- LVEF:
-
Left ventricular ejection fraction
- NYHA:
-
New York Heart Associationa
- CRP:
-
C-reactive protein
References
Cooper LT Jr (2009) Myocarditis. N Engl J Med 360:1526–1538
Imanaka-Yoshida K (2020) Inflammation in myocardial disease: from myocarditis to dilated cardiomyopathy. Pathol Int 70:1–11
Japanese Circulation Society (JCS) Task Force Committee on Chronic Myocarditis (1996) Guideline for diagnosing chronic myocarditis. Japanese Circulation Society (JCS) task force committee on chronic myocarditis. Jpn Circ J 60:263–264
JCS Joint Working Group (2011) Guidelines for diagnosis and treatment of myocarditis (JCS 2009): digest version. Circ J 75:734–743
Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr, Olsen EG, Schoen FJ (1987) Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1:3–14
Maisch B, Bültmann B, Factor S, Gröne H-J, Hufnagel G, Kawamura K, Kühl U, Olsen E, Pankuweit S, Virmani R, McKenna W, Richardson P, Thiene G, Schultheiss H, Sekiguchi M (1999) World Heart Federation consensus conferences’s def- inition of inflammatory cardiomyopathy (myocarditis): report from two expert committees on histology and viral cardiomyopathy. Heartbeat 4:3–4
Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Heliö T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM, European Society of Cardiology Working Group on Myocardial and Pericardial Diseases (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(2636–2648):2648a–2648d
Caforio ALP, Malipiero G, Marcolongo R, Iliceto S (2017) Myocarditis: a clinical overview. Curr Cardiol Rep 19:63
Weintraub RG, Semsarian C, Macdonald P (2017) Dilated cardiomyopathy. Lancet 390:400–414
Nakayama T, Sugano Y, Yokokawa T, Nagai T, Matsuyama TA, Ohta-Ogo K, Ikeda Y, Ishibashi-Ueda H, Nakatani T, Ohte N, Yasuda S, Anzai T (2017) Clinical impact of the presence of macrophages in endomyocardial biopsies of patients with dilated cardiomyopathy. Eur J Heart Fail 19:490–498
Kindermann I, Kindermann M, Kandolf R, Klingel K, Bultmann B, Muller T, Lindinger A, Bohm M (2008) Predictors of outcome in patients with suspected myocarditis. Circulation 118:639–648
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(264–269):W264
Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 10:142
Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, Zembala M, Polonski L, Rozek MM, Wodniecki J (2001) Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 104:39–45
Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A (2003) Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 107:857–863
De Cobelli F, Pieroni M, Esposito A, Chimenti C, Belloni E, Mellone R, Canu T, Perseghin G, Gaudio C, Maseri A, Frustaci A, Del Maschio A (2006) Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol 47:1649–1654
Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, Klingel K, Kandolf R, Sechtem U, Cooper LT, Bohm M (2012) Update on myocarditis. J Am Coll Cardiol 59:779–792
Frustaci A, Russo MA, Chimenti C (2009) Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 30:1995–2002
Bulut D, Scheeler M, Wichmann T, Borgel J, Miebach T, Mugge A (2010) Effect of protein A immunoadsorption on T cell activation in patients with inflammatory dilated cardiomyopathy. Clin Res Cardiol 99:633–638
Escher F, Kuhl U, Lassner D, Poller W, Westermann D, Pieske B, Tschope C, Schultheiss HP (2016) Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. Clin Res Cardiol 105:1011–1020
Merken J, Hazebroek M, Van Paassen P, Verdonschot J, Van Empel V, Knackstedt C, Abdul Hamid M, Seiler M, Kolb J, Hoermann P, Ensinger C, Brunner-La Rocca HP, Poelzl G, Heymans S (2018) Immunosuppressive therapy improves both short- and long-term prognosis in patients with virus-negative nonfulminant inflammatory cardiomyopathy. Circ Heart Fail 11:4228
Hufnagel G, Pankuweit S, Richter A, Schonian U, Maisch B (2000) The European study of epidemiology and treatment of cardiac inflammatory diseases (ESETCID). First Epidemiol Results Herz 25:279–285
Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szygula-Jurkiewicz B, Nowak J, Polonski L, Dyrbus K, Badzinski A, Mercik G, Zembala M, Wodniecki J, Rozek MM (2006) Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 97:899–904
Tsukada B, Terasaki F, Shimomura H, Otsuka K, Otsuka K, Katashima T, Fujita S, Imanaka-Yoshida K, Yoshida T, Hiroe M, Kitaura Y (2009) High prevalence of chronic myocarditis in dilated cardiomyopathy referred for left ventriculoplasty: expression of tenascin C as a possible marker for inflammation. Hum Pathol 40:1015–1022
Camargo PR, Okay TS, Yamamoto L, Del Negro GM, Lopes AA (2011) Myocarditis in children and detection of viruses in myocardial tissue: implications for immunosuppressive therapy. Int J Cardiol 148:204–208
Stewart GC, Lopez-Molina J, Gottumukkala RV, Rosner GF, Anello MS, Hecht JL, Winters GL, Padera RF, Baughman KL, Lipes MA (2011) Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure. Circ Heart Fail 4:71–78
Dennert R, van Paassen P, Wolffs P, Bruggeman C, Velthuis S, Felix S, van Suylen RJ, Crijns HJ, Cohen Tervaert JW, Heymans S (2012) Differences in virus prevalence and load in the hearts of patients with idiopathic dilated cardiomyopathy with and without immune-mediated inflammatory diseases. Clin Vaccine Immunol 19:1182–1187
Kuethe F, Franz M, Jung C, Porrmann C, Reinbothe F, Schlattmann P, Egerer R, Mall G (2017) Outcome predictors in dilated cardiomyopathy or myocarditis. Eur J Clin Invest 47:513–523
Angelini A, Crosato M, Boffa GM, Calabrese F, Calzolari V, Chioin R, Daliento L, Thiene G (2002) Active versus borderline myocarditis: clinicopathological correlates and prognostic implications. Heart 87:210–215
Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, Friedrich MG, Klingel K, Lehtonen J, Moslehi JJ, Pedrotti P, Rimoldi OE, Schultheiss HP, Tschope C, Cooper LT Jr, Camici PG (2020) Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail 13:7405
Mack M (2018) Inflammation and fibrosis. Matrix Biol 68–69:106–121
Kallwellis-Opara A, Dorner A, Poller WC, Noutsias M, Kuhl U, Schultheiss HP, Pauschinger M (2007) Autoimmunological features in inflammatory cardiomyopathy. Clin Res Cardiol 96:469–480
Staudt A, Bohm M, Knebel F, Grosse Y, Bischoff C, Hummel A, Dahm JB, Borges A, Jochmann N, Wernecke KD, Wallukat G, Baumann G, Felix SB (2002) Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 106:2448–2453
Miyauchi K, Daida H (2010) Clinical significance of intensive lipid-lowering therapy using statins in patients with coronary artery disease: LDL-cholesterol: the lower, the better; is it true for Asians? (Pro). Circ J 74:1718–1730
Zhou Q, Liao JK (2010) Pleiotropic effects of statins. - Basic research and clinical perspectives. Circ J 74:818–826
Tajiri K, Shimojo N, Sakai S, Machino-Ohtsuka T, Imanaka-Yoshida K, Hiroe M, Tsujimura Y, Kimura T, Sato A, Yasutomi Y, Aonuma K (2013) Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice. Cardiovasc Drugs Ther 27:413–424
Wada H, Dohi T, Miyauchi K, Shitara J, Endo H, Doi S, Naito R, Konishi H, Tsuboi S, Ogita M, Kasai T, Hassan A, Okazaki S, Isoda K, Shimada K, Suwa S, Daida H (2016) Preprocedural high-sensitivity C-reactive protein predicts long-term outcome of percutaneous coronary intervention. Circ J 81:90–95
Allin KH, Bojesen SE, Nordestgaard BG (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27:2217–2224
Markanday A (2015) Acute phase reactants in infections: evidence-based review and a guide for clinicians. Open Forum Infect Dis 2:ofv098
Ukena C, Kindermann M, Mahfoud F, Geisel J, Lepper PM, Kandolf R, Bohm M, Kindermann I (2014) Diagnostic and prognostic validity of different biomarkers in patients with suspected myocarditis. Clin Res Cardiol 103:743–751
Kuhl U, Noutsias M, Seeberg B, Schannwell M, Welp LB, Schultheiss HP (1994) Chronic inflammation in the myocardium of patients with clinically suspected dilated cardiomyopathy. J Card Fail 1:13–25
Kawai C (1999) From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99:1091–1100
Acknowledgements
The authors wish to acknowledge Hitoshi Moriuchi, Haruna Hirai, and Eriko Masuda for their expert technical assistance.
Funding
Keiichi Hirono and Fukiko Ichida are supported by grants from The Ministry of Education, Culture, Sports, Science and Technology in Japan (Grant-in-Aid for scientific Research Nos. 18K07785). This was also partly supported by Japan Heart Foundation Research Grant on Dilated Cardiomyopathy (to KIY) and Japan Agency for Medical Research and Development (under Grant Number 20ek0109476h0001 to KIY).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interests
The authors declare that they have no competing interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Hirono, K., Takarada, S., Okabe, M. et al. Clinical significance of chronic myocarditis: systematic review and meta-analysis. Heart Vessels 37, 300–314 (2022). https://doi.org/10.1007/s00380-021-01914-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00380-021-01914-y